Saturday 17 October 2026
Export OKUR’s income statement to Excel — free account
OnKure Therapeutics, Inc.
OKUR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 72.8% and free cash flow grew 22.1%, each against the same quarter a year earlier.
2.10
0.03
−1.41%
Follow OKUR
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 59.50 | 17.90 | 9.80 | 7.69 | 1.70 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 171.80 | 95.98 | 112.95 | 20.00 | 9.40 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 23 | 32 | 48 | 8 | 35 | 45 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | (12) | (19) | (40) | (52) | (35) | (53) | (60) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (12) | (19) | (40) | (52) | (35) | (53) | (60) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | (1) | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (63.83) | (95.98) | (21.90) | (21.20) | (124.41) | (15.28) | (4.40) | |||||
| Cash flow | — | — | — | (64.22) | (91.40) | (20.94) | (19.33) | (121.73) | (14.83) | (3.83) | |||||
| Capex | — | — | — | (0.04) | (0.12) | (0.11) | (0.14) | (0.87) | (0.02) | 0.00 | |||||
| Free cash flow | — | — | — | (64.26) | (91.52) | (21.04) | (19.48) | (122.59) | (14.84) | (3.84) | |||||
| Book value | — | — | — | 115.63 | 249.53 | 81.14 | 40.81 | 98.60 | 30.12 | 4.16 | |||||
| Shares, m | — | — | — | 0 | 0 | 2 | 2 | 0 | 3 | 14 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (13) | (19) | (38) | (47) | (35) | (51) | (52) | ||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | (13) | (19) | (38) | (48) | (35) | (51) | (52) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 22 | 50 | 148 | 99 | 26 | 102 | 55 | ||||
| Total debt | — | — | — | 46 | 93 | — | 1 | — | — | — | |||||
| Net debt | — | — | — | (25) | (54) | (148) | (101) | (30) | (111) | (59) | |||||
| Shareholders’ equity | — | — | — | 23 | 51 | 147 | 100 | 28 | 104 | 56 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (97.52) | (48.22) | (38.01) | (39.63) | (49.07) | (69.93) | (67.24) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 38.12 | 59.67 | (75.68) | (42.04) | 3,772.54 | (5,304.43) | (74.39) | |||||
Negative figures in brackets.
Charts ten years each
OnKure Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VXRT VAXART, INC. | $92.4M | 2.8× | 2.1× | −31.58% (below 0%: shrinking) | n/m | +117.38% (above 0%: growing) | 100.00% | (48.45%) | Compare |
| TNYA Tenaya Therapeutics, Inc. | $91.6M | — (loss-making) | — | — | n/m | +76.45% (above 0%: growing) | 100.00% | (3,971.89%) | Compare |
| RLYB Rallybio Corporation | $89.1M | 2.0× | — (loss-making) | 0.00% | n/m | +648.02% (above 0%: growing) | 100.00% | 0.00% | Compare |
| OKUR OnKure Therapeutics, Inc. | $86.3M | — (loss-making) | — | — | n/m | +22.05% (above 0%: growing) | 0.00% | 0.00% | |
| KZIA Novogen Limited | $84.6M | — (loss-making) | — (loss-making) | — | −32.67% (below 0%: shrinking) | −51.71% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AARD Aardvark Therapeutics, Inc. | $84.5M | — (loss-making) | — | — | n/m | −77.14% (below 0%: shrinking) | — | 0.00% | Compare |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | $83.8M | — (loss-making) | — (loss-making) | −92.09% (below 0%: shrinking) | n/m | −78.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| EQ Equillium, Inc. | $83.7M | — (loss-making) | — (loss-making) | −52.32% (below 0%: shrinking) | n/m | −38.67% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| NMRA Neumora Therapeutics, Inc. | $80.2M | — (loss-making) | — | — | n/m | +24.45% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $84.5M | — | — | −41.95% | — | −7.11% | 100.00% | 0.00% |
OnKure Therapeutics, Inc. (OKUR) key facts
- OnKure Therapeutics, Inc. (OKUR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, OKUR traded at $2.10, a market capitalization of $86.3 million.
- Return on equity was −74.4% and debt-to-equity 0.00.